gip glp 1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Upcoming wave of hormone-based therapies
Description
Survodutide Dosing# In the Phase 2 obesity trial, survodutide was administered as once-weekly subcutaneous injections at doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg
GLP-1 drugs are expensive enough to be out of reach for most people, unless they're covered by insurance
Metformin commonly causes gastrointestinal upset and vitamin B12 depletion with long-term use
However, the peptide is degraded by the enzymes DPP-IV and neutral endopeptidase 24.11 (Holst, 2007)
